Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

450 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. Nieto Y, et al. Among authors: bassett r. Lancet Haematol. 2017 Jun;4(6):e283-e292. doi: 10.1016/S2352-3026(17)30080-7. Epub 2017 May 15. Lancet Haematol. 2017. PMID: 28522110 Free PMC article. Clinical Trial.
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.
Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Tam CS, et al. Among authors: bassett r. Blood. 2009 Apr 30;113(18):4144-52. doi: 10.1182/blood-2008-10-184200. Epub 2009 Jan 23. Blood. 2009. PMID: 19168784 Free PMC article.
Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.
Khouri IF, Bassett R, Poindexter N, O'Brien S, Bueso-Ramos CE, Hsu Y, Ferrajoli A, Keating MJ, Champlin R, Fernandez-Vina M. Khouri IF, et al. Among authors: bassett r. Cancer. 2011 Oct 15;117(20):4679-88. doi: 10.1002/cncr.26091. Epub 2011 Mar 31. Cancer. 2011. PMID: 21455998 Free PMC article.
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL Jr, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. Sharma M, et al. Among authors: bassett rl jr. Cancer. 2012 May 1;118(9):2507-15. doi: 10.1002/cncr.26517. Epub 2011 Sep 1. Cancer. 2012. PMID: 21887685 Free PMC article. Clinical Trial.
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Ciurea SO, et al. Among authors: bassett r. Leuk Lymphoma. 2012 May;53(5):901-6. doi: 10.3109/10428194.2011.631159. Epub 2012 Jan 3. Leuk Lymphoma. 2012. PMID: 21988645 Free PMC article. Clinical Trial.
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. Nieto Y, et al. Among authors: bassett r. Biol Blood Marrow Transplant. 2012 Nov;18(11):1677-86. doi: 10.1016/j.bbmt.2012.05.011. Epub 2012 May 27. Biol Blood Marrow Transplant. 2012. PMID: 22643322 Free PMC article.
Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation.
Ma Q, Li D, Nurieva R, Patenia R, Bassett R, Cao W, Alekseev AM, He H, Molldrem JJ, Kroll MH, Champlin RE, Sale GE, Afshar-Kharghan V. Ma Q, et al. Among authors: bassett r. Biol Blood Marrow Transplant. 2012 Aug;18(8):1174-81. doi: 10.1016/j.bbmt.2012.05.014. Epub 2012 Jun 1. Biol Blood Marrow Transplant. 2012. PMID: 22664751 Free PMC article.
Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.
Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Ciurea SO, et al. Among authors: bassett r. Biol Blood Marrow Transplant. 2012 Dec;18(12):1835-44. doi: 10.1016/j.bbmt.2012.07.003. Epub 2012 Jul 11. Biol Blood Marrow Transplant. 2012. PMID: 22796535 Free PMC article. Clinical Trial.
450 results